ROCKVILLE, Md. and SHANGHAI, China, Nov. 6, 2023 /PRNewswire/ -- I-Mab (Nasdaq: IMAB) (the "Company"), a global biotechnology company focused on bringing highly differentiated medicines to patients around the world through the discovery, development, and commercialization of novel immunotherapies and biologics, today announced its in-person participation in two conferences in November 2023, the Jefferies London Healthcare Conference and the Piper Sandler 35th Annual Healthcare Conference. Details of the conferences and management presentation are as follows:
Jefferies London Healthcare Conference (In Person)
Presentation Time | Tuesday, November 14th at 10:30 a.m. GMT (5:30 a.m. EST) |
Presenters | Mr. Raj Kannan, CEO |
Webcast link | https://wsw.com/webcast/jeff287/imab/1828028 |
Meetings | One-on-one and small group meetings: Nov 14 – 16, 2023 |
Management | Mr. Raj Kannan, CEO |
For more information, please contact your Jefferies representative.
Piper Sandler 35th Annual Healthcare Conference (In Person)
Presentation Time | Thursday, November 30th at 8:30 a.m. EST |
Presenters | Mr. Raj Kannan, CEO |
Meetings | One-on-one and small group meetings: Nov 28 – 30, 2023 |
Management | Mr. Raj Kannan, CEO |
For more information, please contact your Piper Sandler representative.
About I-Mab
I-Mab (Nasdaq: IMAB) is a global biotechnology company focused on bringing highly differentiated medicines to patients around the world through the discovery, development, and commercialization of novel immunotherapies and biologics. I-Mab's innovative pipeline is driven by internal R&D's Fast-to-Proof-of-Concept, Fast-to-Market development strategies, and through global partnerships. For more information, please visit https://www.i-mabbiopharma.com and follow us on LinkedIn, X, formerly known as Twitter, and WeChat.
I-Mab Contacts
Investors | Media |
Tyler Ehler | Gigi Feng |
Senior Director, Investor Relations | Chief Communications Officer |
This email address is being protected from spambots. You need JavaScript enabled to view it. | This email address is being protected from spambots. You need JavaScript enabled to view it. |
| Last Trade: | US$1.10 |
| Daily Change: | 0.12 11.77 |
| Daily Volume: | 2,679,641 |
| Market Cap: | US$89.490M |
November 14, 2024 November 06, 2024 September 16, 2024 September 10, 2024 | |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
